Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$8.05 +4.4%	$5.63	$3.76 ▼ $46.80	$49.22M	2.69	208,188 shs	66,378 shs
EDIT Editas Medicine	$2.16 +9.6%	$1.58	$0.91 ▼ $6.05	$164.92M	2.1	2.58 million shs	2.81 million shs
EPRX Eupraxia Pharmaceuticals	$4.17 +8.0%	$3.77	$2.20 ▼ $4.48	$149.94M	0.65	13,203 shs	10,162 shs
FTLF FitLife Brands	$13.26 -5.3%	$14.13	$9.83 ▼ $17.75	$124.53M	0.81	17,630 shs	16,251 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	0.00%	+7.08%	+32.02%	-33.93%	-38.32%
EDIT Editas Medicine	0.00%	+3.14%	+30.46%	+39.72%	-61.07%
EPRX Eupraxia Pharmaceuticals	0.00%	-1.91%	+0.52%	-5.37%	+42.18%
FTLF FitLife Brands	0.00%	-2.17%	+2.64%	+2.34%	-6.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALGS Aligos Therapeutics	4.4397 of 5 stars	3.5	4.0	4.8	2.7	1.7	0.6
EDIT Editas Medicine	4.2358 of 5 stars	3.1	2.0	4.2	2.8	2.5	1.3
EPRX Eupraxia Pharmaceuticals	2.4539 of 5 stars	3.6	1.0	0.0	3.3	0.0	0.6
FTLF FitLife Brands	4.1776 of 5 stars	3.7	3.0	0.0	1.9	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALGS Aligos Therapeutics	3.00	Buy	$70.00	769.57% Upside
EDIT Editas Medicine	2.29	Hold	$5.36	148.32% Upside
EPRX Eupraxia Pharmaceuticals	3.25	Buy	$10.50	151.80% Upside
FTLF FitLife Brands	3.33	Buy	$20.50	54.60% Upside

Current Analyst Ratings Breakdown

Latest ALGS, FTLF, EPRX, and EDIT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	EPRX Eupraxia Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Speculative Buy
5/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $4.00
4/29/2025	EDIT Editas Medicine	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
4/28/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$3.00
4/28/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00
3/31/2025	ALGS Aligos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
3/17/2025	FTLF FitLife Brands	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALGS Aligos Therapeutics	$3.27M	15.05	N/A	N/A	$30.65 per share	0.26
EDIT Editas Medicine	$35.84M	5.05	N/A	N/A	$4.27 per share	0.51
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	$0.03 per share	N/A
FTLF FitLife Brands	$63.86M	1.95	$0.70 per share	19.05	$3.04 per share	4.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALGS Aligos Therapeutics	-$87.68M	-$17.51	N/A	N/A	N/A	-1,283.19%	-114.34%	-64.58%	8/5/2025 (Estimated)
EDIT Editas Medicine	-$153.22M	-$3.04	N/A	N/A	N/A	-340.96%	-80.13%	-50.99%	8/6/2025 (Estimated)
EPRX Eupraxia Pharmaceuticals	-$28.22M	-$0.76	N/A	N/A	N/A	N/A	-219.64%	-96.00%	8/6/2025 (Estimated)
FTLF FitLife Brands	$5.30M	$0.84	15.69	12.05	N/A	13.38%	28.03%	15.13%	N/A

Latest ALGS, FTLF, EPRX, and EDIT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	FTLF FitLife Brands	$0.24	$0.20	-$0.04	$0.20	N/A	N/A
5/12/2025	Q1 2025	EDIT Editas Medicine	-$0.51	-$0.43	+$0.08	-$0.92	$0.79 million	$4.66 million
5/6/2025	Q1 2025	ALGS Aligos Therapeutics	-$2.80	-$2.11	+$0.69	-$2.11	$0.33 million	$0.31 million
5/6/2025	Q1 2025	EPRX Eupraxia Pharmaceuticals	-$0.19	-$0.21	-$0.02	-$0.21	N/A	N/A
3/27/2025	Q4 2024	FTLF FitLife Brands	$0.22	$0.21	-$0.01	N/A	N/A	N/A
3/20/2025	Q4 2024	EPRX Eupraxia Pharmaceuticals	-$0.20	-$0.21	-$0.01	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FTLF FitLife Brands	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALGS Aligos Therapeutics	N/A	3.81	3.81
EDIT Editas Medicine	N/A	3.75	3.75
EPRX Eupraxia Pharmaceuticals	N/A	4.17	4.17
FTLF FitLife Brands	0.28	1.50	0.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALGS Aligos Therapeutics	60.43%
EDIT Editas Medicine	71.90%
EPRX Eupraxia Pharmaceuticals	N/A
FTLF FitLife Brands	2.32%

Insider Ownership

Company	Insider Ownership
ALGS Aligos Therapeutics	4.80%
EDIT Editas Medicine	2.10%
EPRX Eupraxia Pharmaceuticals	N/A
FTLF FitLife Brands	61.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALGS Aligos Therapeutics	90	6.11 million	3.27 million	No Data
EDIT Editas Medicine	230	83.71 million	80.98 million	Optionable
EPRX Eupraxia Pharmaceuticals	29	35.96 million	N/A	N/A
FTLF FitLife Brands	20	9.39 million	3.56 million	Not Optionable

ALGS, FTLF, EPRX, and EDIT Headlines

Recent News About These Companies

FitLife Brands, Inc. (NASDAQ:FTLF) Sees Large Decline in Short Interest

June 2, 2025 | marketbeat.com

Tootsie Roll among names set to join Russell 3000 Index, Growgeneration, Veru set to leave

May 30, 2025 | msn.com

FitLife Brands (NASDAQ:FTLF) Downgraded by Wall Street Zen to Hold

May 24, 2025 | marketbeat.com

FitLife Brands (NASDAQ:FTLF) sheds 11% this week, as yearly returns fall more in line with earnings growth

May 21, 2025 | finance.yahoo.com

FitLife Brands, Inc. (PNK:FTLF) Q1 2025 Earnings Call Transcript

May 17, 2025 | msn.com

FitLife Brands, Inc.: FitLife Brands Announces First Quarter 2025 Results

May 17, 2025 | finanznachrichten.de

FitLife Brands, Inc. (FTLF) Q1 2025 Earnings Call Transcript

May 16, 2025 | seekingalpha.com

FitLife Brands Announces First Quarter 2025 Results

May 15, 2025 | globenewswire.com

Insights into FitLife Brands's Upcoming Earnings

May 14, 2025 | benzinga.com

FitLife Brands, Inc. (NASDAQ:FTLF) is largely controlled by hedge funds shareholders who own 56% of the company

May 5, 2025 | finance.yahoo.com

FitLife Brands Announces First Quarter Earnings Call

May 5, 2025 | globenewswire.com

Fitlife Brands Has Potential For Continued Profitable Growth

May 4, 2025 | seekingalpha.com

FitLife Brands Announces Board Transition

April 28, 2025 | globenewswire.com

FitLife Brands, Inc. to Present at Planet MicroCap Showcase: VEGAS 2025 on April 23

April 22, 2025 | quiverquant.com

FitLife Brands Unveils New Corporate Presentation

April 22, 2025 | tipranks.com

FitLife Brands to Present at Planet MicroCap Investor Conference

April 22, 2025 | globenewswire.com

FitLife Brands (FTLF) Surges 13.1%: Is This an Indication of Further Gains?

April 21, 2025 | zacks.com

Insider Buying: FitLife Brands, Inc. (NASDAQ:FTLF) Director Purchases 3,000 Shares of Stock

April 17, 2025 | insidertrades.com

Here's Why We Think FitLife Brands (NASDAQ:FTLF) Might Deserve Your Attention Today

April 14, 2025 | finance.yahoo.com

FitLife Brands, Inc. (NASDAQ:FTLF) Director Matthew Lingenbrink Buys 2,800 Shares

April 3, 2025 | insidertrades.com

FitLife Brands, Inc. (PNK:FTLF) Q4 2024 Earnings Call Transcript

March 29, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS, FTLF, EPRX, and EDIT Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

$8.05 +0.34 (+4.41%)

Closing price 04:00 PM Eastern

Extended Trading

$8.15 +0.10 (+1.24%)

As of 06:36 PM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Editas Medicine NASDAQ:EDIT

$2.16 +0.19 (+9.64%)

Closing price 04:00 PM Eastern

Extended Trading

$2.15 -0.01 (-0.65%)

As of 07:50 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Eupraxia Pharmaceuticals NASDAQ:EPRX

$4.17 +0.31 (+8.03%)

Closing price 03:59 PM Eastern

Extended Trading

$4.18 +0.01 (+0.24%)

As of 04:04 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

FitLife Brands NASDAQ:FTLF

$13.26 -0.74 (-5.29%)

Closing price 04:00 PM Eastern

Extended Trading

$13.36 +0.10 (+0.76%)

As of 06:20 PM Eastern

FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time